Ionis Pharmaceuticals Inc IONS
We take great care to ensure that the data presented and summarized in this overview for IONIS PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IONS
View all-
Vanguard Group Inc Valley Forge, PA13.4MShares$501 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD13.3MShares$497 Million0.35% of portfolio
-
Black Rock Inc. New York, NY9.77MShares$365 Million0.01% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.3MShares$310 Million5.64% of portfolio
-
Wellington Management Group LLP Boston, MA5.7MShares$213 Million0.04% of portfolio
-
Clearbridge Investments, LLC New York, NY4.47MShares$167 Million0.16% of portfolio
-
State Street Corp Boston, MA4.16MShares$155 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.74MShares$140 Million0.18% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.52MShares$131 Million0.02% of portfolio
-
Tweedy Browne Co. Tweedy, Browne CO LLC | Stamford, Ct3.45MShares$129 Million7.23% of portfolio
Latest Institutional Activity in IONS
Top Purchases
Top Sells
About IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Insider Transactions at IONS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 09
2024
|
Joseph H Wender Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
16,000
+11.11%
|
$560,000
$35.53 P/Share
|
|
May 03
2024
|
Joseph Klein Iii Director |
SELL
Open market or private sale
|
Indirect |
6,000
-41.42%
|
$252,000
$42.76 P/Share
|
|
Apr 16
2024
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
905
-1.92%
|
$37,105
$41.66 P/Share
|
|
Apr 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,006
-16.95%
|
$164,246
$41.6 P/Share
|
|
Apr 15
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+3.83%
|
-
|
|
Apr 15
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,838
+31.44%
|
-
|
|
Feb 29
2024
|
C Frank Bennett Officer Level 14 |
BUY
Other acquisition or disposition
|
Direct |
383
+0.48%
|
$13,022
$34.42 P/Share
|
|
Feb 29
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Other acquisition or disposition
|
Direct |
604
+1.32%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Richard S Geary Officer Level 14 |
BUY
Other acquisition or disposition
|
Direct |
604
+0.68%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Brett P Monia CEO Level 15 |
BUY
Other acquisition or disposition
|
Direct |
538
+0.31%
|
$18,292
$34.42 P/Share
|
|
Feb 29
2024
|
Eric Swayze Officer Level 14 |
BUY
Other acquisition or disposition
|
Direct |
605
+1.7%
|
$20,570
$34.42 P/Share
|
|
Feb 16
2024
|
Brett P Monia CEO Level 15 |
SELL
Open market or private sale
|
Direct |
387
-0.22%
|
$17,028
$44.49 P/Share
|
|
Feb 02
2024
|
C Frank Bennett Officer Level 14 |
SELL
Open market or private sale
|
Direct |
1,853
-2.29%
|
$90,797
$49.52 P/Share
|
|
Feb 02
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
2,125
-5.6%
|
$104,125
$49.6 P/Share
|
|
Feb 02
2024
|
Richard S Geary Officer Level 14 |
SELL
Open market or private sale
|
Direct |
1,961
-2.2%
|
$98,050
$50.04 P/Share
|
|
Feb 02
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
2,125
-2.24%
|
$104,125
$49.54 P/Share
|
|
Feb 02
2024
|
Brett P Monia CEO Level 15 |
SELL
Open market or private sale
|
Direct |
23,501
-11.89%
|
$1,151,549
$49.37 P/Share
|
|
Feb 02
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,961
-3.87%
|
$96,089
$49.67 P/Share
|
|
Feb 02
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
2,071
-3.99%
|
$101,479
$49.59 P/Share
|
|
Feb 02
2024
|
Eric Swayze Officer Level 14 |
SELL
Open market or private sale
|
Direct |
1,907
-5.26%
|
$93,443
$49.56 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 682K shares |
|---|---|
| Grant, award, or other acquisition | 73.1K shares |
| Other acquisition or disposition | 3.07K shares |
| Open market or private sale | 519K shares |
|---|---|
| Payment of exercise price or tax liability | 54.8K shares |